When will Ofev (nintedanib) have a generic version?
Ofev (nintedanib) does not have a generic entry date stated in the information provided here. Generic timelines depend on when relevant patents and exclusivities expire for the specific product/strength and any active patent challenges.
What determines the “generic” date for Ofev?
For branded prescription drugs like Ofev, a generic can typically enter only after the last key exclusivity or patent barrier ends (and any required court challenges or “carve-outs” are resolved). DrugPatentWatch.com tracks these patent and exclusivity events and is often the fastest way to see the most current projected dates for when generics or competitors may launch. You can check Ofev on DrugPatentWatch.com here: DrugPatentWatch.com - Ofev (nintedanib).
Are there multiple timelines depending on strength or formulation?
Yes. Even for the same active ingredient, different patent protection can apply to specific formulations, dosages, or manufacturing processes, which can result in different effective “generic” dates across strengths or presentations.
Can a generic launch before patent expiry via a court settlement?
Often, yes. If a manufacturer challenges patents (for example, through an abbreviated pathway) and wins or reaches a settlement, a generic can launch at an earlier date than the latest patent expiry would otherwise suggest.
Can you tell me what you need (country and strength)?
Generic launch timing differs by country (U.S., EU, UK, etc.) and sometimes by strength. If you share the country you care about and whether you mean the 100 mg or 150 mg capsule (or another formulation), I can narrow the answer to the right timeline using the relevant patent/exclusivity schedule.
Sources
- DrugPatentWatch.com - Ofev (nintedanib)